Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 12. Analyst Marc Goodman from Leerink Partners reiterated a Buy rating on the stock and has a $260.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Marc Goodman has given his Buy rating due to a combination of factors influencing Biogen’s future prospects. One key reason is the expected acceleration in Leqembi’s growth, particularly with the anticipated approval of blood-based diagnostics for Alzheimer’s disease and the eventual approval of subcutaneous and induction maintenance dosing. These developments are poised to enhance the company’s performance in the long run.
Moreover, Biogen’s management is focusing on its Alzheimer’s disease, lupus, and other immunology franchises to drive growth, which is crucial as the company’s multiple sclerosis franchise is experiencing a decline. Although the current numbers have been disappointing, with the 2025 EPS guidance falling below consensus, Marc Goodman believes in the company’s potential to return to growth at these valuation levels. This potential, despite the challenges, supports the Outperform rating.
According to TipRanks, Goodman is a 4-star analyst with an average return of 6.1% and a 46.67% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Ltd., Axsome Therapeutics, and ACADIA Pharmaceuticals.